Search Medical Condition
Please enter condition
Please choose location from dropdown

Aarschot, Belgium Clinical Trials

A listing of Aarschot, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (189) clinical trials

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

In the majority of European countries, the primary management of chronic heart failure patients is performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies have shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides ...

Phase

0.54 miles

Learn More »

Extension Study to Evaluate the Long-Term Safety Tolerability and Maintenance of Effect of BIIB074

This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen. This is an extension study to 1014802-203.

Phase

7.8 miles

Learn More »

Restoration of the Microbiome Through Superdonor Selection

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD) characterized by a diffuse mucosal inflammation, extending proximally from the rectum and causing symptoms of bloody diarrhea. The complex pathogenesis of IBD remains largely unknown. Manipulation of the enteric microbiota to restore normobiosis has therapeutic potential in IBD. Fecal ...

Phase N/A

7.92 miles

Learn More »

LEGION Hinge Safety and Efficacy Study

The objective of this study is to demonstrate statistically significant improvements in the original Knee Society Clinical Score (KSCS) from baseline to 1 and 2 years in subjects using the LEGION Hinge Knee System. The focus of the 1 and 2 year analyses will be on safety and efficacy. The ...

Phase N/A

8.13 miles

Learn More »

C-Leg 3 and C-Leg 4 Study in Transfemoral Amputees

During the last two decades many microprocessor controlled knee joints (MPK) appeared on the market.The newly developed C-Leg 4 aims to provide improved standing function while in the same time offering technology of knees previous version (C-Leg 3). Since added functional benefit of a knee joint cannot be anticipated just ...

Phase

8.13 miles

Learn More »

Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study

The objective of this study is to estimate the safety and performance of Journey II BCS TKS. Specifically, the study will establish revision rate, treatment- and device-related complications, and clinical outcomes in a large sample of subjects who received the study device. Subjects are screened consecutively, beginning at the earliest ...

Phase N/A

8.13 miles

Learn More »

Effectiveness of the Geriatric Activation Program Pellenberg (GAPP) on the Geriatric Rehabilitation Ward

The aim of this study is to investigate the effectiveness of our developed week-treatment program GAPP (Geriatric Activation Program Pellenberg), on strength, balance, speed, functionality and cognition, with the main goal to achieve a better independence for ADL. Each day of the week an exercise program of 45 minutes is ...

Phase N/A

8.13 miles

Learn More »

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or S zary Syndrome (SS)

The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Szary Syndrome that have recently achieved disease control with previous systemic therapy.

Phase

9.43 miles

Learn More »

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil ...

Phase

9.43 miles

Learn More »

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

PXT3003 is a rational design, fixed combination of low-dose (RS) baclofen, naltrexone hydrochloride and D-sorbitol. The use of PXT3003 in a multicenter, randomised, placebo controlled phase II study (CLN-PXT3003-01) was well-tolerated and safe in patients with CMT1A for the three dose-levels investigated (Attarian et al., 2014). The intermediate and high ...

Phase

9.43 miles

Learn More »